BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37435919)

  • 21. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal?
    Mariotti S; Barbesino G; Caturegli P; Marinó M; Manetti L; Pacini F; Centoni R; Pinchera A
    J Clin Endocrinol Metab; 1995 Feb; 80(2):468-72. PubMed ID: 7852506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E; Soydal C; Araz M; Aras G; Ibis E
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer.
    Neshandar Asli I; Siahkali AS; Shafie B; Javadi H; Assadi M
    Mol Imaging Radionucl Ther; 2014 Jun; 23(2):54-9. PubMed ID: 24963446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
    Spencer CA; Takeuchi M; Kazarosyan M; Wang CC; Guttler RB; Singer PA; Fatemi S; LoPresti JS; Nicoloff JT
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1121-7. PubMed ID: 9543128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroglobulin is a poor predictor of differentiated thyroid cancer in patients who undergo surgery for thyroid nodular diseases.
    Rigbi S; Joshua BZ; Baraf L; Yoel U; Fraenkel M
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1311-1319. PubMed ID: 36205785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
    Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
    Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma.
    Giovanella L; Verburg FA; Trimboli P; Imperiali M; Keller F; Ceriani L
    Clin Chem Lab Med; 2019 Jul; 57(8):1185-1191. PubMed ID: 30835250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma.
    Qin J; Yu Z; Guan H; Shi L; Liu Y; Zhao N; Shan Z; Han C; Li Y; Teng W
    Dis Markers; 2015; 2015():648670. PubMed ID: 26600670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].
    Zöphel K; Wunderlich G; Liepach U; Koch R; Bredow J; Franke WG
    Nuklearmedizin; 2001 Oct; 40(5):155-63. PubMed ID: 11727628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [
    Albano D; Tulchinsky M; Dondi F; Mazzoletti A; Lombardi D; Bertagna F; Giubbini R
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):461-468. PubMed ID: 32794104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer.
    Spencer C; Fatemi S
    Best Pract Res Clin Endocrinol Metab; 2013 Oct; 27(5):701-12. PubMed ID: 24094640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of Tg and TgAb for metastasis following ablation in patients with differentiated thyroid carcinoma coexistent with Hashimoto thyroiditis.
    Chai H; Zhu ZJ; Chen ZQ; Yu YL
    Endocr Res; 2016 Aug; 41(3):218-22. PubMed ID: 27158852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
    Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
    Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
    Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer.
    Aydin F; Sipahi M; Budak ES; Oner AO; Demirelli S; Erkilic M; Gungor F
    Ann Nucl Med; 2016 Jan; 30(1):60-7. PubMed ID: 26462671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.
    Crane MS; Strachan MW; Toft AD; Beckett GJ
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):421-32. PubMed ID: 23847033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody.
    Liu Y
    Nucl Med Commun; 2016 Jun; 37(6):577-82. PubMed ID: 26813991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.